| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| "Do non-R&D intensive industries benefit of spillovers from public research? The case of the Agro-food industry |
0 |
0 |
0 |
15 |
0 |
0 |
2 |
58 |
| Aligning Strategies for Growth and Talent Management in Creative Professional Service Firms |
0 |
0 |
1 |
23 |
0 |
3 |
9 |
97 |
| Biotech Innovation in Europe's Food and Drink Processing Industry: Promise, Barriers and Exploitation |
0 |
0 |
0 |
20 |
0 |
3 |
9 |
120 |
| Business models: A challenging agenda |
0 |
2 |
3 |
51 |
1 |
8 |
21 |
161 |
| Cléopâtre et son goûteur |
0 |
0 |
0 |
3 |
0 |
1 |
3 |
175 |
| Community as a locus of innovation: co-innovation with users in the creative industries |
0 |
1 |
1 |
48 |
4 |
7 |
11 |
123 |
| Competing business models in the french biotech industry |
0 |
0 |
0 |
21 |
0 |
0 |
5 |
98 |
| Creation and growth of high-tech SMEs: the role of the local environment |
0 |
0 |
0 |
0 |
0 |
1 |
10 |
29 |
| Creation of biotech SMEs in France |
0 |
0 |
0 |
1 |
0 |
2 |
8 |
55 |
| Development of SMEs and heterogeneity of trajectories: the case of biotechnology in France |
0 |
0 |
0 |
0 |
1 |
3 |
11 |
47 |
| Disassembly and reassembly on digital technology and creative industries |
0 |
0 |
0 |
42 |
0 |
2 |
10 |
78 |
| Diversification and hybridisation in firm knowledge bases in nanotechnologies |
0 |
0 |
0 |
89 |
0 |
1 |
11 |
393 |
| Diversification and hybridization in firm knowledge bases in nanotechnologies |
0 |
0 |
0 |
10 |
0 |
3 |
5 |
110 |
| Do Science and Money Go Together? The Case of the French Biotech Industry |
0 |
0 |
0 |
16 |
0 |
1 |
6 |
92 |
| Editor's Introduction: Scientific and Technical Human Capital |
0 |
0 |
0 |
28 |
0 |
3 |
10 |
109 |
| Emergence des nanotechnologies: Vers un nouveau "modèle industriel "? |
0 |
0 |
0 |
38 |
0 |
4 |
9 |
191 |
| Entre discrimination et autocensure. Les carrières des femmes dans l'enseignement supérieur et la recherche |
0 |
0 |
0 |
84 |
0 |
4 |
5 |
387 |
| Explorer pour innover, répliquer pour séduire |
0 |
0 |
0 |
5 |
0 |
4 |
7 |
54 |
| French Biotech Start-Ups and Biotech Clusters in France. The Importance of Geographic Proximity |
0 |
0 |
0 |
23 |
0 |
0 |
6 |
131 |
| From Business model to Business model portfolio in the european biopharmaceutical industry |
0 |
0 |
0 |
56 |
0 |
0 |
4 |
144 |
| From individual scientific visibility to collective competencies: the example of an academic department in social science |
0 |
0 |
0 |
6 |
1 |
2 |
8 |
120 |
| From sectoral to horizontal public policies: the evolution of support for biotechnology in Europe, 1994-2001 |
0 |
0 |
0 |
0 |
0 |
2 |
4 |
14 |
| Global Contests in the Production of Business Knowledge |
0 |
0 |
0 |
2 |
0 |
5 |
12 |
61 |
| How do Academics adopt new practices during a reform ? The Evolution of doctoral education in France 1992-2009 |
0 |
0 |
0 |
14 |
0 |
0 |
4 |
43 |
| How long is co-operation in genomics sustainable? |
0 |
0 |
0 |
2 |
0 |
0 |
5 |
25 |
| Idiosyncratic distances: Impact of mobile technology practices on role segmentation and integration |
0 |
0 |
0 |
0 |
1 |
3 |
5 |
21 |
| Industry Life Cycle, Knowledge Generation and Technological Networks |
0 |
0 |
0 |
20 |
0 |
0 |
5 |
87 |
| Innovation et création dans le jeu vidéo: comment concilier exploration exploration et exploitation |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
11 |
| Institutional change and professional practices: The case of French doctoral education |
0 |
0 |
0 |
8 |
0 |
1 |
1 |
49 |
| Is the Creation and Development of Biotech SMEs Localised? Conclusions Drawn from the French Case |
0 |
0 |
0 |
0 |
0 |
3 |
8 |
42 |
| LARGE PLAYERS IN THE NANOGAME: DEDICATED NANOTECH SUBSIDIARIES OR DISTRIBUTED NANOTECH CAPABILITIES? |
0 |
0 |
0 |
10 |
0 |
1 |
9 |
84 |
| La confiance: un mode de coordination dont l'utilisation dépend de ses conditions de production |
0 |
0 |
0 |
44 |
0 |
2 |
5 |
306 |
| Learning in MNCs: How subsidiary managers do (and do not) create global solutions |
0 |
0 |
0 |
30 |
1 |
3 |
4 |
60 |
| Orchestrating networks in the biopharmaceutical industry: small hub firms can do it |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
51 |
| PIS AS BOUNDARY SPANNERS, SCIENCE AND MARKET SHAPERS |
0 |
0 |
1 |
3 |
2 |
3 |
9 |
51 |
| PME de biotechnologie: Plusieurs Business models en concurrence |
0 |
0 |
0 |
22 |
1 |
3 |
7 |
155 |
| Profile of public laboratories, industrial partnerships and organisation of R & D: the dynamics of industrial relationships in a large research organisation |
0 |
0 |
0 |
15 |
0 |
5 |
6 |
93 |
| Project Management: Learning by violating principles |
0 |
0 |
0 |
0 |
0 |
1 |
6 |
23 |
| Project management learning by violating principales |
0 |
0 |
0 |
0 |
0 |
5 |
6 |
20 |
| Project management: learning by breaking the rules |
0 |
0 |
0 |
231 |
0 |
2 |
13 |
652 |
| REJUVENATING NANOCLUSTERS WITH 'SLEEPING ANCHORS': PRE-ADAPTATION AND LIFE CYCLE |
0 |
0 |
0 |
12 |
1 |
2 |
10 |
90 |
| Recherche ou temps perdu ? Vers une intégration des tâches administratives au métier d'enseignant chercheur |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
30 |
| Reputational spillovers: evidence from french architecture |
0 |
0 |
0 |
10 |
0 |
0 |
8 |
39 |
| Start-up mid and long term strategic management using a business model portfolio |
0 |
0 |
0 |
6 |
0 |
0 |
3 |
37 |
| Stimulating Knowledge Search Routines and Architecture Competences: The Role of Organizational Context and Middle Management |
1 |
1 |
1 |
3 |
2 |
6 |
12 |
47 |
| Subsidiary managers’ knowledge mobilizations: Unpacking emergent knowledge flows |
0 |
0 |
0 |
1 |
1 |
4 |
10 |
57 |
| Surfing on institutions: When temporary actors in organizational fields respond to institutional pressures |
0 |
0 |
0 |
2 |
0 |
1 |
3 |
20 |
| THE DETERMINANTS OF THE SCIENCE-BASED CLUSTER GROWTH: THE CASE OF NANOTECHNOLOGIES |
0 |
0 |
0 |
26 |
0 |
1 |
7 |
73 |
| THE FUTURE OF NANOTECHNOLOGIES |
0 |
0 |
0 |
20 |
0 |
3 |
8 |
92 |
| THE ROLE OF PRACTICES IN INSTITUTIONAL CHANGE THE EVOLUTION OF DOCTORAL PROGRAMS IN FRANCE 1990 – 2008 |
0 |
0 |
0 |
38 |
1 |
3 |
3 |
56 |
| Technological Knowledge Base, R&D Organization Structure and Alliance Formation: Evidence from the Biopharmaceutical Industry |
0 |
0 |
0 |
67 |
0 |
0 |
10 |
326 |
| Technological agglomeration and the emergence of clusters and networks in nanotechnology |
0 |
0 |
0 |
213 |
2 |
9 |
18 |
688 |
| Technological agglomeration and the emergence of clusters and networks in nanotechnology |
0 |
0 |
0 |
22 |
0 |
3 |
11 |
118 |
| Technological competition, strategies of the firms and the choice of the first users: the case of road guidance technologies |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
29 |
| The Carrers of Social Science Doctoral Graduates in France: the Influence of How the Research was Carried Out |
0 |
0 |
0 |
6 |
1 |
2 |
13 |
114 |
| The Dynamics of Innovation Networks |
0 |
0 |
0 |
239 |
0 |
4 |
10 |
414 |
| The Evolution of the French Public Policy to Promote Biotech Innovation: The Case of Genomics |
0 |
0 |
0 |
12 |
0 |
3 |
6 |
44 |
| The Simultaneous Shaping of Organization and Technology Within Co-operative Agreements |
0 |
0 |
0 |
6 |
0 |
0 |
1 |
59 |
| The future of drug discovery and development: Shifting emphasis towards personalized medicine |
0 |
0 |
0 |
0 |
0 |
2 |
7 |
35 |
| The inhibiting factors that principal investigators experience in leading publicly funded research projects |
0 |
0 |
0 |
7 |
0 |
3 |
6 |
44 |
| The role of regional institutional entrepreneurs in the emergence of clusters in nanotechnologies |
0 |
1 |
1 |
298 |
1 |
5 |
13 |
893 |
| Turning scientific and technological human capital into economic capital: the experience of biotech start-ups in France |
0 |
0 |
1 |
18 |
0 |
3 |
9 |
108 |
| Underpinning Strategic Behaviours and Posture of Principal Investigators in Transition/Uncertain Environments |
0 |
0 |
0 |
3 |
0 |
0 |
3 |
32 |
| Understanding the emergence and deployment of “nano” S&T |
0 |
0 |
0 |
29 |
0 |
3 |
12 |
124 |
| University Technology Transfer offices: the search for identity to build legimacy |
0 |
0 |
1 |
23 |
2 |
7 |
13 |
159 |
| WHEN CELEBRITY DESTROYS ARTISTIC REPUTATION: THE CASE OF FRENCH ARCHITECTS |
0 |
0 |
0 |
21 |
2 |
5 |
6 |
76 |
| When technological discontinuities and disruptive business models challenge dominant industry logics: insights from the drugs industry |
0 |
0 |
0 |
51 |
0 |
1 |
9 |
139 |
| Total Working Papers |
1 |
5 |
10 |
2,113 |
25 |
162 |
514 |
8,563 |
LogEc is hosted by the
Örebro University School of Business.